Skip to main
LUNG

Pulmonx (LUNG) Stock Forecast & Price Target

Pulmonx (LUNG) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 67%
Buy 0%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

Pulmonx is a medical technology company that has a promising future based on its strong fundamentals. With an expected sequential improvement in year-over-year revenue growth through 2026 and a focused U.S. strategy, the company is poised for a return to growth in both domestic and international markets. Additionally, Pulmonx's cost restructuring initiatives have resulted in improved margins and a lower net loss, making it a potential investment opportunity.

Bears say

Pulmonx is facing a transitional period as the company refocuses on operational discipline and commercial reacceleration, with fourth quarter revenue declining to $22.6M amid weaker U.S. performance and a net loss of $14.0M. While the company has a solid cash position, future capital pressure could be a concern if U.S. treatment center utilization and patient conversion do not reaccelerate without additional sales force expansion that could compress margins. Key risks include Clinical/Regulatory, Partnership and Financial, Commercial, Legal and Intellectual Property, and Market Share, while potential catalysts include the upcoming earnings cycle and the company's efforts to improve sales productivity and operating expense discipline.

Pulmonx (LUNG) has been analyzed by 6 analysts, with a consensus rating of Buy. 67% of analysts recommend a Strong Buy, 0% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Pulmonx and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Pulmonx (LUNG) Forecast

Analysts have given Pulmonx (LUNG) a Buy based on their latest research and market trends.

According to 6 analysts, Pulmonx (LUNG) has a Buy consensus rating as of Jun 3, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $5.58, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $5.58, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Pulmonx (LUNG)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.